Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Life After Pfizer: MicuRx Forms JV To Develop Antibiotics In China

This article was originally published in PharmAsia News

Executive Summary

The JV with Shanghai Zhangjiang Biomedical Industry Venture Capital will fund the development and commercialization of MicuRx’s novel antibiotic MRX-I for the Chinese market.

You may also be interested in...



Under Industry Pressure, China Blinks On Restricting Use Of Anti-infectives - Or Does It?

SHANGHAI - China's State Council Aug. 4 released a formal draft of a new policy to address the abuse of anti-infectives and is soliciting public comments. Surprising analysts, the draft policy is less strict than a previous version that had circulated around industry, leaving the future of China's anti-infective market more difficult to predict

Pfizer Senior VP And Head Of Worldwide PharmaTherapeutics Research Rod MacKenzie On Moving R&D To China: An Interview With PharmAsia News (Part 2 of 2)

Pfizer Inc.'s Rod MacKenzie, senior VP and Head of Worldwide PharmaTherapeutics Research talked with PharmAsia News about the evolution of Pfizer's virtual R&D approach in China and larger Asia. Pfizer announced last week that it would be opening a new R&D center for antibacterials in Shanghai after closing its antibacterial R&D plant in Groton, Conn. The move marks the first dedicated R&D unit for a specific therapy area in Asia.

Pfizer Shake Up Continues With Key Exits From Emerging Markets

In the wake of CEO Jeff Kindler's abrupt departure earlier this week, Pfizer has announced two key departures from its emerging markets team, suggesting greater changes may be on the way at the world's largest drug maker

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

SC079698

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel